Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuanghuang Shengbai Granules in lung adenocarcinoma with chemotherapy-induced myelosuppression
ChiCTR2200061371Phase 4Recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of shuanghuang shengbai in Non-small cell lung cancer adenocarcinoma (NSCLC) (3 arms), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoints: TCM clinical syndrome score for lung cancer at day 21 and Metabolomics test at day 21. Started Dec 2021; status: recruiting.
02
Drugs
shuanghuang shengbai
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200061371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061371.